Dec, 2020
Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance.
Acta medica Okayama
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- Volume
- 74
- Number
- 6
- First page
- 545
- Last page
- 550
- Language
- English
- Publishing type
- DOI
- 10.18926/AMO/61215
Polymorphisms in methotrexate transporter pathways have been associated with methotrexate toxicities and clearance. Recent genome-wide association studies have revealed that the SLCO1B1 T521C variant is associated with methotrexate elimination. We present a case of a pediatric patient with acute lymphoblastic leukemia who suffered from persistently high plasma methotrexate concentrations and acute kidney injuries after the admin-istration of a medium dose of methotrexate. Subsequent genetic analysis showed that he was a carrier of dys-functional genetic variants associated with methotrexate clearance. This case highlights that polymorphisms of methotrexate transporter pathways can adversely affect methotrexate elimination in a clinically significant manner.
- Link information
- ID information
-
- DOI : 10.18926/AMO/61215
- Pubmed ID : 33361876